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“The promise of agricultural biotechnology is immense. Advances in
this technology will result in crops with a wide range of desirable
traits that will directly benefit farmers, consumers, and the
environment and increase global food production and quality.”––
Seeds of Opportunity: an Assessment Of The Benefits, Safety, and
Oversight of Plant Genomics and Agricultural Biotechnology, United
States House of Representatives, 1999
“Food biotech is dead.”––Henry I. Miller, Hoover Institute, Stanford
University (Eichenwald et al., 2001)
1Ms. Foreman was scheduled to deliver this presentation at the meeting, but was unable to do so.
I believe agricultural biotechnology does indeed offer the promise of substantial
benefits to farmers, consumers, and the environment. However, after almost
twenty years of industry advocacy and government promotion, the American
people have not embraced this new technology. Spurred by such events as the
StarLink™ corn contamination and European rejection of genetically modified
foods, there is an increasingly visible and contentious debate in this country
about the potential risks and benefits of agricultural biotechnology and its
appropriate role in our lives. Radical environmentalists trash biotech fields.
Obdurate biotech advocates trash the intelligence and integrity of anyone who
disagrees with them.
If we want to realize the potential benefits of agricultural biotechnology, we
must achieve agreement and compromise. Beginning that process requires
taking a realistic view of the public’s willingness to accept agricultural
biotechnology, appreciating some of the factors that contribute to continuing
public concern, and considering changes in government regulation that might
increase the public trust that is so vital to greater acceptance and full realization
of agricultural biotechnology’s promise.
PUBLIC ACCEPTANCE OF AGRICULTURAL BIOTECHNOLOGY AND
GENETICALLY MODIFIED FOODS
Dozens of polls have examined the level of public acceptance of agricultural
biotechnology and genetically modified foods in United States. Each poll is
structured differently, asking slightly different questions, and getting somewhat
different answers. If you support biotechnology, you can find a poll that agrees
with your point of view. If you oppose the technology, you can find a poll that
condemns it. Not surprisingly, poll questions are often structured in a manner
to assure a response consistent with the views of the poll’s sponsor.
But it is possible to get a snapshot of the general level of public acceptance.
I reviewed five polls, taken between 1999 and 2001, and totaled the positive
and negative responses (see below). There is good news and bad in the results
of these surveys. The good news is that only one poll showed more people with
negative than positive opinions. The bad news is that none of the polls showed
strong public support for genetic engineering. Only one question came close to
eliciting a positive response from two-thirds of those polled.
Survey/Questions Total Total
positive negative
International Food Information Council Foundation
(January 19–21, 2001)
Would you purchase foods modified by biotechnology
in ways that provided direct and obvious consumer
benefits such as: fresher, tastier produce?  58% 38%
reduced saturated fat? 46% 17%
Do you expect benefits to your family from biotech
within 5 years? 64% 22%
Pew Foundation Initiative on Food and Biotechnology
(January 22–28, 2001)
Are genetically modified foods: basically safe / unsafe  48%  21%
(unsafe)
Harris Poll (June 8–12, 2000)
Do benefits of developing / growing GE plants
outweigh risks? 38% 48%
(risks greater)
Gallup Poll (March 30–April 2, 2000)
Do you support use of biotechnology in food / agriculture? 48% 41%
National Science Foundation / Texas A&M
Public Policy Research Institute (April–May 2000) (Priest, 2000)
Do you believe GE will improve our way of life
in next 20 years? 53% 30%
Perhaps more troubling, Susan Horning Priest (2000), writing in Nature
Biotechnology, reported that Americans are less enthusiastic about genetic
engineering than about other recently introduced technologies.
FAVORABLE ATTITUDES TOWARD NEW TECHNOLOGIES
The NSF/Texas A&M survey asked respondents their views of whether
particular technologies would improve their lives:
Technology Positive response
Computers/information technology 88%
Solar energy 88%
Telecommunications 82%
The Internet 72%
Space exploration 62%
Genetic engineering 53%
UNFAVORABLE ATTITUDES: GENETIC ENGINEERING VERSUS
NUCLEAR ENERGY
The NSF/Texas A&M survey found that Americans are equally as negative
about genetic engineering as they are about nuclear energy, a technology that
has had limited application in the United States because of a lack of public
acceptance:
Technology Positive response
Genetic engineering 30%
Nuclear energy 32%
Now many biotech advocates take comfort in the fact that polls show many
Americans are still not aware of genetic engineering. They assume that, as
people become more familiar with the technology, they will feel more
comfortable with it. Unfortunately, research indicates that familiarity with
agricultural biotechnology does not breed affection. Priest (2000) compared
responses to genetic engineering over seventeen years. The number of people
who had negative attitudes toward agricultural biotechnology almost doubled,
rising from 16 to 30%:
Genetic Engineering Will Make
the Quality of Life Worse Positive response
1982 16%
1986 22%
1999 30%
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Last year we accepted the election of the President of the United States by
something less than a convincing majority. We are much more demanding when
it comes to new products. They do not survive unless they gain popularity and
do it quickly. A new technology that affects the safety and quality of our food
supply will almost surely have to secure an overwhelming level of public
acceptance if it is to survive.
WHY AMERICANS ARE UNENTHUSIASTIC ABOUT GENETICALLY
MODIFIED FOODS
I can identify three reasons why Americans have embraced computers and cell
phones and medical biotechnology, but are less accepting of genetically
modified foods.
First, food is special. The manufacturers of genetically modified products
think they are purveying commodities. Consumers believe they are tinkering
with something more basic to the human psyche: a “cultural metaphor for life.”
We eat to live, but we also live to eat. Food provides energy and essential
nutrients, but food is more than fuel for the body. It is sustenance for the soul.
From the Apple in the Garden of Eden to the golden arches on the highway,
food is a key component of human civilization. Food is a cultural and religious
icon. Throughout history, people have been defined by what they are obligated
or forbidden to eat. Even in twenty-first century America what you eat reveals
who you are and where you are from. If you want to experience true cultural
isolation, walk into a New York deli and order corned beef on white with mayo.
Food is intensely personal. In 1996, the Agriculture Council of America
commissioned an intensive study of our emotional attachments to food. They
found that food is integrally tied to nurturance, bonding and love. Participants
in the study viewed unsafe food as a hostile invader of their homes and an
assault on themselves and their families.
Second, agricultural biotechnology presents an unbalanced distribution of risks
and benefits. When it comes to food, most of us are risk-averse. This is
especially true if the risk is imposed on us by someone else, is invisible, and
lacks a countervailing direct and specific personal benefit.
It is easy to see why genetically modified foods light up all the risk-aversion
receptors. The products on the market today have no direct consumer benefit.
They were developed to enhance the economic fortunes of farmers and
When it comes to food, most of us are risk-averse. This is
especially true if the risk is imposed on us by someone
else, is invisible, and lacks a countervailing direct and
specific personal benefit.
chemical companies. Lowering farmers’ input costs is important to farmers, but
not to American consumers. Lowering the cost of producing corn, does not
translate to cheaper meat at the supermarket.
There are promises of nutritionally superior products, but we cannot eat
promises. And, the adamant refusal to label genetically modified products
cannot help but increase consumer suspicion that these foods carry some risk.
Most consumers believe that if you have to hide it, there must be something
wrong with it. In short, there is no reason for consumers to willingly accept any
risk from genetically engineered food.
Third, acceptance of agricultural biotechnology is affected by the social and
political context into which it has been introduced, including instantaneous
communication and globalization. No product or technology comes to market in
a vacuum. Unfortunately, the advent of genetically modified crops has
coincided with a rash of food-safety disasters. Because we live in an era of
instantaneous communication, the details of those disasters are flashed into our
homes. Because we eat from a global plate, we can never be sure that a food
safety disaster half-way around the world will not end up on our dining-room
table.
Finally, the very fact of globalization creates discomfort for many people.
Agricultural biotechnology is associated with increasing global corporate
power. This, coupled with a diminishing level of trust in both private and
public institutions compounds the problem for those seeking to gain accep-
tance of agricultural biotechnology.
THE ROLE OF GOVERNMENT IN ASSURING SAFETY AND ACCEPTANCE
Given all these impediments to public acceptance of genetically modified food
products, it would seem reasonable that supporters of agricultural biotechnol-
ogy would benefit from, even insist upon, a food safety regulatory system in the
United States so rigorous and credible and above reproach that it cannot fail to
dispel doubt and instill public trust.
The United States government and agricultural biotechnology industry chose
another course. Our government, especially the Food and Drug Administration
(FDA):
• opted for a system that favored a rush to market over assurance of safety
and acceptance. The White House, in an election year, became actively
involved in writing FDA’s 1992 Policy Statement on Foods Derived from
New Plant Varieties. Vice President Quayle described the Statement as
“regulatory reform,” designed to help American agricultural biotechnology
companies gain advantage in a new field. This effort to speed genetically
modified foods to market has served instead to deny genetically modified
products the most valuable assets they could acquire: a rigorous and
transparent pre-market safety approval by FDA, and resulting public
comfort level.
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• contorted existing statutes to regulate a technology that was never
contemplated when the relevant laws were written in 1906 and 1958.
Contrast this to the course chosen in the European Union, which enacted
new law specifically designed to deal with “novel foods.”
• established what amounts to a system of “nonregulation” (based on
McGarity and Hansen, 2001). Foods altered by agricultural biotechnology
are not subject to rigorous premarket safety testing and FDA approval.
Today FDA does not require notice that a firm intends to market a
genetically modified food organism so long as the firm concludes that its
product is “generally recognized as safe” (GRAS). Changes under
consideration by the agency will not require FDA to approve products
before they are marketed.
HOW FDA AVOIDS REGULATION OF, AND RESPONSIBILITY FOR,
GENETICALLY MODIFIED FOODS
The FDA has determined that adding a new gene to a conventional food falls
under the 1958 Food Additive provisions of the Food Drug and Cosmetic Act,
unless the resulting genetically modified food is “substantially equivalent” to a
conventional food that is GRAS.
Substantial equivalence—limiting the factors that would cause a product to be
considered different. The new genetically modified food is considered “substan-
tially equivalent” to its conventional counterpart unless the transfer involved
genes coding for fats, proteins, or carbohydrates that might cause allergic
reactions, are known to be toxic, or change the nutritional value of the food.
Some FDA scientists urged that at least basic toxicological testing be done on
all genetically modified foods. The FDA has established no protocols to detect
unanticipated effects, no chemical analyses of the molecular characteristics of
the altered food, no tests for stability of the transferred gene or of the key
nutrients and toxicants.
Accepting the manufacturer’s assertion that a product is GRAS. For all practical
purposes a company that produces a genetically modified food is the judge of
whether the product falls within the “GRAS” category. The GRAS determination
relies almost exclusively on a manufacturer’s finding that the food meets this
requirement.
When the FDA approves a petition for a new food additive, it publishes a
regulation stating that FDA finds that the additive is safe, making public the
data that support its decision, establishing requirements for the use and
labeling of the additive.
If a company claims that its product is GRAS, FDA must either accept the
data presented to it by the company or take on the burden of disproving the
safety of the product. If the FDA accepts the company’s data, it takes no
responsibility for the safety of the product. There is no Federal Register notice
and no explanation of reasoning. Virtually all of the FDA-regulated genetically
modified products now on the market got there because the producing
company claimed the product is GRAS. The company receives a letter from
FDA, the operative language of which is that the company has determined that
the product is the same as a safe product.
For example, on January 27, 1995, FDA wrote to Monsanto regarding the
Roundup Ready® soybean, stating, “…it is our understanding that, based on the
safety and nutritional assessment you have conducted, you have concluded that
the new soybean variety is not materially different in composition, safety, or any
other relevant parameter from soybean varieties now on the market… as you
are aware, it is Monsanto’s continued responsibility to ensure that foods the
firm markets are safe, wholesome and in compliance with all applicable legal
and regulatory requirements.”
FDA and the biotechnology industry express surprise that anyone objects to
the current system of bringing modified foods to market. The argue that all the
new products are tested are rigorously reviewed. However, the products are
tested by the company that makes them, and, although FDA reviews summaries
of the tests, the agency does not provide a formal pre-market safety approval of
genetically modified foods. The FDA never states that it finds a new genetically
modified product is safe. It is hard to account for the inability of the FDA and
industry to see that allowing a company that produces a GM food to determine
that it is safe—based on data collected by the company and opinions of experts
that the company may have hired—creates the potential for serious problems.
The GRAS process assumes that a company with a large investment in a new
product will never be unduly influenced by its self-interest in the product’s
development and success. It assumes that a company and its experts will never
make a mistake in their assessments. A regulatory system that does not require
the regulatory agency to take public responsibility for allowing a new and
If a company claims that its product is GRAS, FDA must
either accept the data presented to it by the company or
take on the burden of disproving the safety of the product.
If the FDA accepts the company’s data, it takes no respon-
sibility for the safety of the product. There is no Federal
Register notice and no explanation of reasoning.
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untried product on the market, and explaining its reasons why, assumes that
a company that must meet its profit goal will never put its own interest above
that of the public and excludes the possibility of human error, is a regulatory
system that is likely to fail both the regulated industry and the public.
The FDA’s decision, in its 1992 Policy Statement, to examine genetically
modified foods on the basis of GRAS has been determined by at least one court
to fall within FDA’s regulatory discretion. The GRAS process has been around
for a long time. It was devised in part to shorten the period of time needed to
move new, but uncontroversial, food additives to market. The question is why
FDA decided to apply this doctrine to move the products of a new and
controversial technology to market.
Again, the record indicates that the Bush administration was eager to give
American companies an advantage in getting a new technology on the market
quickly. In addition, the FDA apparently was driven to pursue this policy of
“nonregulation” in order to avoid asking Congress either to write new law
needed to address the new technology appropriately or to provide the
additional staff and resources required to perform more intensive safety reviews.
The decision was shortsighted and unwise. The policy has failed the test of
public trust. Under the pressure of increasing public criticism, FDA asked for
comments on the existing system. It received 35,000 responses, most
unfavorable. The agency is now trying to buy a little more credibility by
making small changes to its review process, but it adamantly refuses to make
the changes necessary to assure the kind of scrutiny that builds public trust.
Instead it has given those who oppose the technology a powerful weapon to
use against the new products.
If the products of agricultural biotechnology are as benign as both industry
and government insist, why not subject them to the most searching scrutiny?
The FDA never states that it finds a new genetically
modified product is safe. It is hard to account for the
inability of the FDA and industry to see that allowing
a company that produces a GM food to determine that it
is safe—based on data collected by the company and
opinions of experts that the company may have hired—
creates the potential for serious problems.
IS IT POSSIBLE TO REGRIND THE LENS AND SECURE CONSUMER
ACCEPTANCE OF BIOTECHNOLOGY?
Scientists and public officials have advocated a regulatory system that inspires
public trust. Perry Adkisson, chair of the National Academy of Sciences
Committee on Genetically Modified Pest-Protected Plants, has stated, “Public
acceptance of these foods ultimately depends on the credibility of the testing
and regulatory process” (Bettleheim, 1999).
And in 1999, Secretary of Agriculture Dan Glickman urged, “With all that
biotechnology has to offer, it is nothing if it’s not accepted. That boils down to
a matter of trust—trust in the science behind the process . . . trust in the
regulatory process that ensures a thorough review. . . .”
Proponents of agricultural biotechnology have tended to dismiss critics as
either ignorant, intellectually dishonest, or extremist. It is a serious mistake.
In the end, the biotechnology industry and its supporters will succeed neither
in insulting people into buying these products nor concealing their presence.
We would all benefit if we could find some way to improve the regulatory
regime, increasing public confidence in the safety of genetically modified foods
without imposing such expense and delay that the industry fails. There is at
least one example where representatives of the stakeholder groups demon-
strated that it is possible to reach some agreement on key issues related to
agricultural biotechnology, as follows.
Cognizant of the increasing disagreement between the trans-Atlantic partners
on this subject, President Prodi of the European Union and President Clinton
appointed a Consultative Forum comprising twenty private individuals, ten
from each side of the Atlantic, to meet and try to reach some consensus. It was
an extremely diverse and impressive group—including a former Prime Minister
of the Netherlands, Nobel Laureate Norman Borlaug, officials of DuPont and
Unilever; a farmer from Portugal and one from Missouri, a consumer advocate
from the United Kingdom and one from the United States, and three scientists
actively engaged in agricultural biotechnology. It also included a scientist from
Environmental Defense, a representative from European Friends of the Earth,
and a bioethicist from Georgetown University. I was privileged to be part of the
American delegation.
We reached agreement and produced a report. None of us loved every line.
Each of us disliked some part of it. But we were able to agree on the following
about agricultural biotechnology:
• It has promise that must not be squandered.
• It can be a major contributor to fighting hunger in the developing world.
• It presents the threat of unforeseen, unintended, negative consequences
that must be addressed.
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• Its successful use requires public trust and that trust will be generated
by a rigorous, comprehensive and open regulatory process, including
mandatory pre-market safety review of each product and a determination
by the appropriate government agency that the product is safe.
• Final products containing novel genetic material should be labeled.
In December 2000 we presented our recommendations (US-EU, 2000),
which—at the urging of industry and government agencies—have been
ignored by Presidents Clinton and Bush. The EU has begun to respond to
the recommendations, positively in most cases.
I disagree with Henry Miller that agricultural biotechnology is doomed.
The recommendations of the US-EU Consultative Forum offer a way to have
the technology and some assurance of safety. The report is evidence that a wide
range of people would like to see agricultural bioechnology move forward and
can agree on changes that would facilitate progress.
Without actions similar to those recommended by the US-EU Biotechnology
Consultative Forum, it is unlikely that agricultural biotechnology will gain the
public trust essential to the fulfillment of its promise.
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